United States - English - NLM (National Library of Medicine)

boiron - croton tiglium seed (unii: 0hk2gzk66e) (croton tiglium seed - unii:0hk2gzk66e) - itching relieved by light rubbing* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - croton tiglium seed (unii: 0hk2gzk66e) (croton tiglium seed - unii:0hk2gzk66e) - itching relieved by light rubbing* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

hahnemann laboratories, inc. - croton tiglium seed (unii: 0hk2gzk66e) (croton tiglium seed - unii:0hk2gzk66e) -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - s-abscisic acid - water soluble granules - s-abscisic acid acid active 200.0 g/kg - growth regulator - berry fruit | grape - table | barlinka | cardinal | flame seedless | grapevine | muscat of hamburg | red emperor | red malaga | - increase fruit maturity or colour | increased red colour

Canada - English - Health Canada

dolisos canada inc. - baptisia tinctoria; sodium borate; mezereum; myosotis arvensis; sodium chloride; poison ivy; croton oil - globules - 2ch; 3ch; 2ch; 2ch; 2ch; 2ch; 3ch - baptisia tinctoria 2ch; sodium borate 3ch; mezereum 2ch; myosotis arvensis 2ch; sodium chloride 2ch; poison ivy 2ch; croton oil 3ch - homeopathic products

United States - English - NLM (National Library of Medicine)

rebel distributors corp - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium 40 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. protonix is contraindicated in patients with known hypersensitivity to any component of the formulation [see description ( 11 ) ] or any substituted benzi

United States - English - NLM (National Library of Medicine)

stat rx usa llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. protonix is contraindicated in patients with known hypersensitivity to any component of the formulation [see description ( 11 ) ] or any substituted benzimida

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. protonix is contraindicated in patients with known hypersensitivity to any component of the formulation [see description (11) ] or any substituted benzimidazo

United States - English - NLM (National Library of Medicine)

silver star brands - plantago major (unii: w2469wno6u) (plantago major - unii:w2469wno6u), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), croton tiglium seed (unii: 0hk2gzk66e) (croton tiglium seed - unii:0hk2gzk66e), toxicodendron radicans leaf (unii: cdh3461u7l) (toxicodendron radicans leaf - unii:cdh3461u7l), smilax ornata root (unii: 2h1576d5wg) (smilax ornata root - unii:2h1576d5wg) - croton tiglium seed 30 [hp_x] in 113 g - indications*: may temporarily relieve signs and symptoms associated with shingles, including stinging pain, skin lesions, itching and burning associated with herpetic eruptions and infections. *as per various homeopathic materia medicas. these indications have not been evaluated by the fda, and product has not been clinically tested. homeopathic gel

Australia - English - Department of Health (Therapeutic Goods Administration)

gamma gurus pty ltd - 47069 - proton therapy system - an assembly of devices used to produce and deliver a transverse and longitudinal dose proton beam to treat localized tumours and other conditions susceptible to treatment by radiation.